NCT02561130 - Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

insulin glargine

Dose is titrated to achieve fasting normoglycemia

DRUG

metformin

Dose is titrated to 1 g bid or maximal tolerated dose

DRUG

Forxiga

Dose is titrated to 10 mg po daily or maximal tolerated dose

BEHAVIORAL

Lifestyle therapy

Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving

Trial Locations (7)

T2T 5C7

University of Calgary, Calgary

R3E 3P4

Health Science Centre, Winnipeg

L8N 3Z5

McMaster University, Hamilton

N6A 4V2

St. Joseph's Hospital, London

N6G 2M1

Western University, London

M4G 3E8

LMC, Toronto

M5C 2T2

St. Michaels's Hospital, Toronto